WGS
The table below shows GeneDx Holdings Corp.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$32.41M | $10.18M | -$16.41M | -$55.56M | -$81.49M | -$42.21M |
| Capital expenditure | $6.45M | $6.13M | $443.00K | $0.00 | $1.38M | $2.08M |
| Investing cash flow | -$17.25M | -$9.41M | $843.00K | -$462.00K | -$3.91M | -$4.99M |
| Dividends paid | - | - | - |
GeneDx Holdings Corp. reported operating cash flow of $33.28M for fiscal year 2025. That is up 216.8% from -$28.50M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$18.73M (FY 2019) to $33.28M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $38.59M | $13.72M | -$438.00K | $132.66M | -$160.00K | -$2.28M |